GLP-1RA治疗儿童和青少年2型糖尿病及肥胖症的研究进展
Research progress on clinical application and safety of GLP-1RA in children and teenagers with type 2 diabetes and obesity
叶芳杏 1伍黎芳 1黎涛1
作者信息
- 1. 梧州市工人医院药学部,梧州 543000
- 折叠
摘要
近年来,我国儿童和青少年2型糖尿病(T2DM)及肥胖发病率逐年升高.然而,目前国内批准用于治疗儿童和青少年T2DM及肥胖的药物有限,且失败率较高.近年来的研究表明,胰高血糖素样肽-1受体激动剂(GLP-1RA)对儿童和青少年T2DM及肥胖患者降糖和减重是有效且短期应用安全性较好,但处于生长发育期的儿童和青少年对GLP-1RA的反应和耐受程度不同于成人,胃肠道不良反应及低血糖发生率明显增高,故需要重视其长期使用的安全性问题,进一步开展更加系统的研究及长期随访评估.
Abstract
In recent years,the incidence rate of type 2 diabetes(T2DM)and obesity in children and teenagers in China is increasing year by year.However,currently there are limited drugs approved domestically for the treat-ment of T2DM and obesity in children and teenagers,and the failure rate is high.In recent years,studies have shown that glucagon like peptide-1 receptor agonists(GLP-1RA)are effective and have good short-term safety in lowering blood sugar and weight loss in children and teenagers with T2DM and obese patients.However,chil-dren and teenagers in the growth and development stage have different reactions and tolerance levels to GLP-1RA compared to adults,and the incidence of gastrointestinal adverse reactions and hypoglycemia is significantly increased.Therefore,it is necessary to pay attention to the safety of their long-term use,and more systematic re-search and long-term follow-up evaluation should be further conducted.
关键词
胰高血糖素样肽-1受体激动剂/儿童/青少年/2型糖尿病/肥胖Key words
glucagon like peptide-1 receptor agonist/children/teenagers/type 2 diabetes/obesity引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据